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A Preliminary Evaluation of Calcitonin and PDN-21 as TUmor Markers
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M. Richez,* G. Bureau,* P. Mommen,* N. Raymakers,* M. Paesmans,* J. Klastersky,*
and the EORTC Lung Cancer Working Party*
Immunoreactive calcitonin (ICT) can he eclopically secreted by lung cancer cells and has been
propo.sed as a tumor marker for bronchial neoplasms. Since PDN-21 (katacalcin or the carboxylterminal flanking peptide of the calcitonin gene) and CT are cosecreted in normal subjects and in
patients wdh medullary thyroid carcinoma (MTC), we soughl lo delermine the potential ulilily of
PDN-21 as a tumor marker for lung cancer We measured carcinoembryonic antigen (CEA), neuronspecific enolase (NSE), iCT. and PDN-21 in 119 lo 378 healthy subjects, 88 to 91 patients wilh benign
pulmonary diseases, and 249 patients wilh advanced lung cancer (108 small cell lung cancers and Ml
other forms). Tumor marker specificity was satisfaclory: the percentage of increased values (grealer
lhan the 95lh percentile of normal subjects) in patients wilh benign pulmonary diseases varied from
9% (NSE, PDN-21) to 12% (CEA). PDN-21 was a more sensdive marker for lung cancer than iCT; the
percenlage of increased values was 44% for PDN-21 versus 19% for iCT, and 51% versus 23% for the
subgroup ofpatients wilh small cell lung cancer (SCLC). PDN-21 concentrations were increased in 69
(34%) of202 patients with a normal iCT level, whereas iCT concentrations were increased in only six
(4%) of 139 patients with a normal PDN-21 level. However, markedly elevated concentrations oflhe
two markers generally occurred in the same patients and the correlation beiween the two markers was
significanl (r, = 0.60; P < O.OI). PDN-21 provided complementary information lo that from the
classical markers NSE and CEA. PDN-21 was thus elevated in seven (47%) qf 16 patients with SCLC
and a normal NSE level, and in 19 (30%) of 63 patients with non-SCLC and a normal CEA level.
Immunodilulion curves of sera wilh elevaled concentrations of PDN-21 were slrictly paraUel to the
.standard curve, suggesting lhal the assay essentially measured authentic PDN-21. These preliminary
results suggest lhal PDN-21 and possibly other CT gene producls are worthwhile in furlher biologic
and clinical investigations in lung cancer (Henry Ford Hosp Med J 1989:37:190-3)

everal authors have reported increases in circulating calcitonin (CT) in various other cancers than medullary thyroid
carcinoma (MTC), parricularly in lung cancer (1-3). The secreted forms are generally larger than monomeric CT (4), and it
is thus more adequate to speak of immunoreactive CT (iCT).
The frequency of etevated values varies much between studies
but has been higher than 50% in some series of patients with
small cell lung cancer (SCLC) (3). Measurement of iCT could
be useful for monitoring the tumor mass in SCIXT (5), but reported series are small and do not include valid comparisons
with classical tumor markers.
PDN-21 (katacalcin or the carboxyt-terminal flanking peptide
of the calcitonin gene) derives from the same precursor as CT
and is cosecreted with CT in healthy subjects and in patients
with MTC (6,7). In our studies of tumor markers for lung cancer
(8,9), we investigated the possibility that this cosecretion might
be present in other cancers than MTC and that PDN-21 might be
a potentially useful tumor marker for lung cancer.

S

Methods
Assays
The four evaluated markers were measured by commercially
available radioimmunoassays; carcinoembryonic antigen
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(CEA) and neuron-specific enotase (NSE) (Pharmacia Inc, Uppsala, Sweden), iCT (INCStar, Stillwater, M N ) , and PDN-21
(Medgenix Diagnostics, Fleurus, Belgium). The assays' detection limits were 40 pglmL for iCT and 7 pglmL for PDN-21, and
undetectable values were assigned levels of 20 pglmL for iCT
and 3.5 pg/mL for PDN-21.
Subjects
Normal values were detennined in 377 healthy subjects for
iCT (251 mates and 126 females; median age 43 years, range 18
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Table 1
Immunoreactive Calcitonin (iCT) and PDN-21
in Lung Cancer
Percenlage of
Elevated Values
vs Nl
vs BPD

Percentiles (pg/raL)
99
95
50

Highesi 'Values
(pg/raL)

65
74
58

948
710
1,048

7,800
2,540
7,800

9,998
9,450
9,998

18,9
23.1
15.6

13.7
16.7
11.3

14
16
14

630
696
624

4,410
2,198
4,410

14,500
10,330
14,500

44.2
50.9
39.0

26.1
33.3
20.6

iCT
All cases
SCLC
NSCLC

1000

PDN-21
All cases
SCLC
NSCLC

s
I

to 84 years) and in 119 for PDN-2t (82 mates and 37 females;
median age 42 years, range 18 to 64 years). We defined the upper
limits of normal values as the 95th percentiles determined in
these groups, ie, 123 pglmL for iCT and 15.7 pglmL for
PDN-2t. The 95th percenfiles for CEA and NSE were 7.5 ngl
mL(n = 316) and ll.O ng/mL (n = 378), respectivety.
Tumor marker specificity was determined in 88 patients with
various benign pulmonary diseases (9) (54 males and 34
females; median age 63 years, range 19 to 87 years).
Tumor markers were evaluated in 249 patients with advanced
lung cancer (214 males and 35 females; median age 59 years,
range 35 to 77 years). Of these patients, 210 had never been
treated before and 39 had recurrent disease after previous antineoplastic therapy (radiotherapy [n = 13], chemotherapy [n =
9], surgery [n = 4], or combined modalities [n = 13]), Tumor
types were as fotlows; 108 SCLC and 141 non-SCLC (NSCLC)
including 80 squamous cett lung cancers, 39 adenocarcinomata,
12 large cell lung cancers, and 10 other forms.

Results
Seram CEA concentrations were elevated in 12% of the patients with benign pulmonary diseases, compared to 10% for
iCT and 9% for NSE or PDN-21, In this population, the 95th
percenfiles were 12.5 ng/mL for CEA, 183 pglmL for iCT, 11.6
ng/mL for NSE, and 24 pglmL for PDN-21.
Individual values of iCT and PDN-21 measured in the three
groups of patients with benign pulmonary diseases, SCLC, or
NSCLC are depicted in Figs 1 and 2, respectivety. The data are
summarized in Table 1. Seram iCT levets were increased in 19%
of the patients with lung cancer compared with increases in
PDN-21 tevels in 44% of the patients. In the subgroup of patients
with SCLC, iCT concentrations were increased in 23% of the
patients compared to 51% for PDN-2t.
As shown in Tabte 2, PDN-21 and iCT were frequently not
increased in the same patients. PDN-21 concentrations were etevated in 69 (34%) of 202 patients with a normal iCT level,
whereas iCT concenti-ations were increased in onty six (4%) of
139 patients with a normal PDN-21 tevel. However, as shown in
Fig 3, markedly etevated values of the two markers generalty occuned in the same patients. Even though the tow values of iCT
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Fig 1—Serum concentrations of immunoreactive calcitonin
(iCT) in patients with benign pulmonary diseases (BPD), smaU
cell lung cancer (SCLC), and non-small cell lung cancers
(NSCLC). The upper Umd of normal (95 th percentile ofthe normal population) is represented by the dotted line.
and PDN-21 did not conelate, the conetafion gradually improved as values increased (Fig 3; r^ = 0.60, P < O.OI).
Not surprisingly, NSE was the most sensitive marker in patients with SCLC (83% had elevated values) whereas CEA was
the most sensitive marker for •NSCLC
• * « (50% had elevated values). However, PDN-21 provided some complementary information to that from the classical tumor markers. PDN-21 was
increased in seven (47%) of 16 patients with SCLC and normal
NSE levels, and in 19 (30%) of 63 patients with NSCLC and normal CEA levels.
In preliminary experiments investigating the possibte immunoheterogeneity of circulating PDN-21, immunoditution curves
of three sera from patients with elevated immunoreactive
PDN-21 levels were found to be parallel to the standard curve
(Fig 4).

Discussion
Many tumor markers have been investigated in lung cancer,
particularly in SCLC where ectopic secretion of various en-
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Table 2
Comparison of Immunoreactive calcitonin (iCT)
and PDN-21 in Patients with Lung Cancer

100000

•
•

10000

•
•
•
_
E

•
•

1000

••
•

too-

10-

•
•
•
•

•

1

••• •

••
•^••••••••*» •

Nonnal
Increased
Total

PDN-21
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Increased

Total

133
6
139

69
41
110
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249
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Fig 2—Serum concentrations of PDN-21. Note that the log
scale extends up to 100,000 pglmL. BPD = benign pulmonary
diseases, SCLC = smad cell lung cancer, and NSCLC = nonsmall cell lung cancers. The upper limit of normal (95th percentile ofthe normal population) is represented by the dotted line.
zymes or hormones is frequently observed (10). The secrefion of
hormones such as CT suggests a histogenic relationship between
SCLC and the pulmonary neuroendocrine celts (10,11). NSE is
currentiy considered to be the best clinical marker for SCLC and
is increasingly used to monitor the therapy of this type of lung
cancer (12). Our study confirms that NSE levets are increased in
over 75% of the patients with SCLC. NSCLC are a heterogeneous group of tumors that progress more slowly and are less
chemosensitive than SCLC. Despite the increasing number of
available markers, CEA remains the "gold standard" for atl
NSCIX! even though it has limited clinical value (13).
Our data indicate that PDN-21 is a new tumor marker for lung
cancer Its specificity was very satisfactory and its sensitivity
was far better than iCT measurement. This increased sensitivity
appeared to be mainly due to the tower timit of normal values.
Even though the concentrations of iCT and PDN-21 were frequently not increased in the same patients, the conelation between the two markers was good for markedly elevated values.
Exceptions, however, were noted in the cosecretion of the two
peptides which has been reported for MTC (7). This suggests an
abnormal processing of CT gene products in some patients with
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Norraal
Increased
Total
*P< 0.0001.
tp < 0.0005.

cancers other than MTC, but further studies are necessary before firm conctusions can be made on this important point.
Circulating CT is immunochemicatty heterogeneous, particularty in cancer patients (4). The use of extraction techniques is
necessary to study correctly CT physiology or CT deficiency
conditions (17,18). It has also been necessary to measure
PDN-21 after serum extraction to demonstrate its cosecretion
with CT in normal subjects (6), but tittle is known about the possible immunochemical heterogeneity of circulating PDN-21.
The nature of secreted immunoreactive PDN-21 by lung cancer
cells remains to be determined, but the strict parallelism of the
immunoditution curves to the standard curve suggests that authentic PDN-21 has been measured. The use of monoclonal antibodies to measure CT-monomer, PDN-21, and other CT gene
products should be useful in defining better the exact nature of
the secreted peptides (19).
Although its clinical value remains to be proven, PDN-21 appeared to provide complementary information to NSE and
CEA, the classical tumor markers for SCLC and NSCLC, respectively. Our study supports the theory that NSCLC can have
similar neuroendocrine biological properties as SCLC. Concentrations of NSE were increased in 43% (data not shown) and
PDN-21 in 39% of our patients with NSCLC. Other authors have
atso reported elevations of endocrine-related markers in substantial proportions of patients with NSCI£ (14,15). These biochemical observations are conoborated by histologic descriptions of neuroendocrine differentiation of some NSCLC)( 16).
The prognostic or therapeutic importance of such neuroendocrine characteristics remains to be determined, but these studies could tead to a new classification of lung cancers which
woutd no tonger be based on sole histologic criteria but also on
biological properties possibly leading to different therapeutic
approaches.
These preliminary data show that PDN-21 is a new tumor
marker for lung cancer which is more sensitive than iCT. Moreover, PDN-21 may provide complementary information to the
classical tumor markers CEA and NSE. This work atso supports
the concept of neuroendocrine differentiation in a as yet undefined subgroup of patients with NSCLC and raises some interesting questions about the processing of CT gene products in
other cancers than MTC.
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Eig3—Correlation between serum concentrations ofPDN-21 and iCT in patients with lung cancer (y = 214 3- 0.83 x;r^ = 0.60; P
< 0.01). For clarity, normal values of both markers have been withdrawn from panel A and are shown in panel B.
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